Ryvu Therapeutics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Ryvu Therapeutics's earnings have been declining at an average annual rate of -16.8%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 24.3% per year.
Belangrijke informatie
-16.8%
Groei van de winst
-9.4%
Groei van de winst per aandeel
| Life Sciences Groei van de industrie | 26.0% |
| Inkomstengroei | 24.3% |
| Rendement op eigen vermogen | -46.7% |
| Nettomarge | -116.3% |
| Volgende winstupdate | 07 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt
Oct 20
We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate
Aug 02Are Investors Undervaluing Ryvu Therapeutics S.A. (WSE:RVU) By 20%?
Jan 25What Type Of Shareholders Own The Most Number of Ryvu Therapeutics S.A. (WSE:RVU) Shares?
Feb 05Shareholders Of Ryvu Therapeutics (WSE:RVU) Must Be Happy With Their 261% Total Return
Dec 14Opbrengsten en kosten
Hoe Ryvu Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 82 | -96 | 146 | 0 |
| 31 Mar 24 | 74 | -94 | 137 | 0 |
| 31 Dec 23 | 67 | -92 | 123 | 0 |
| 30 Sep 23 | 84 | -73 | 121 | 0 |
| 30 Jun 23 | 88 | -66 | 110 | 0 |
| 31 Mar 23 | 80 | -75 | 91 | 0 |
| 31 Dec 22 | 68 | -84 | 85 | 0 |
| 30 Sep 22 | 50 | -94 | 79 | 0 |
| 30 Jun 22 | 37 | -105 | 72 | 0 |
| 31 Mar 22 | 36 | -92 | 68 | 0 |
| 31 Dec 21 | 35 | -79 | 64 | 0 |
| 30 Sep 21 | 26 | -72 | 59 | 0 |
| 30 Jun 21 | 25 | -61 | 56 | 0 |
| 31 Mar 21 | 30 | -41 | 51 | 0 |
| 31 Dec 20 | 37 | -32 | 51 | 0 |
| 30 Sep 20 | 38 | -40 | 53 | 0 |
| 30 Jun 20 | 41 | -32 | 54 | 0 |
| 31 Mar 20 | 17 | -41 | 45 | 0 |
| 31 Dec 19 | 34 | -44 | 56 | 0 |
| 30 Sep 19 | 53 | -53 | 43 | 0 |
| 30 Jun 19 | 19 | -60 | 19 | 0 |
| 31 Mar 19 | 116 | -28 | 93 | 0 |
| 31 Dec 18 | 52 | -23 | 26 | 0 |
| 30 Sep 18 | 49 | 2 | 40 | 0 |
| 30 Jun 18 | 96 | 14 | 65 | 0 |
| 31 Mar 18 | 102 | 21 | 61 | 0 |
| 31 Dec 17 | 105 | 6 | 58 | 0 |
| 30 Sep 17 | 104 | 13 | 55 | 0 |
| 30 Jun 17 | 97 | 14 | 53 | 0 |
| 31 Mar 17 | 80 | 10 | 48 | 0 |
| 31 Dec 16 | 66 | 3 | 47 | 0 |
| 30 Sep 16 | 60 | 0 | 49 | 0 |
| 30 Jun 16 | 60 | -1 | 45 | 0 |
| 31 Mar 16 | 57 | 3 | 40 | 0 |
| 31 Dec 15 | 56 | 6 | 35 | 0 |
| 30 Sep 15 | 51 | 7 | 28 | 0 |
| 30 Jun 15 | 48 | 7 | 26 | 0 |
| 31 Mar 15 | 46 | 7 | 26 | 0 |
| 31 Dec 14 | 41 | 6 | 24 | 0 |
| 30 Sep 14 | 43 | 4 | 22 | 0 |
| 30 Jun 14 | 35 | 2 | 20 | 0 |
| 31 Mar 14 | 27 | -1 | 17 | 0 |
| 31 Dec 13 | 22 | -2 | 16 | 0 |
Kwaliteitswinsten: RVU is currently unprofitable.
Groeiende winstmarge: RVU is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: RVU is unprofitable, and losses have increased over the past 5 years at a rate of 16.8% per year.
Versnelling van de groei: Unable to compare RVU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: RVU is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-0.7%).
Rendement op eigen vermogen
Hoge ROE: RVU has a negative Return on Equity (-46.65%), as it is currently unprofitable.